Kimmig, Lucas M. http://orcid.org/0000-0001-8297-0278
Liao, Chuanhong
Bag, Remzi http://orcid.org/0000-0001-8313-6015
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (5T32HL007605)
United Therapeutics Corporation
Article History
Received: 12 July 2019
Accepted: 9 December 2019
First Online: 7 January 2020
Compliance with Ethical Standards
:
: Lucas Kimmig has no relevant conflicts of interest to disclose. Lucas Kimmig received support from the NIH T32 Training Grant in Respiratory Biology (5T32HL007605). Chuanhong Liao has no relevant conflict of interest to disclose. Remzi Bag has served as consultant/speaker for Actelion Pharmaceuticals, Cipla, Gilead Sciences, and Bayer; and has received research grants from Gilead Sciences, Reata Pharma, Actelion, Medtronics, Liquidia Technologies, PhaseBio, Arena Pharma, Lung Biotechnology and United Therapeutics Corp. This work was supported by a grant from United Therapeutics Corporation. The funding source was not involved in the data collection, analysis, or interpretation, and did not have the right to approve or disapprove publication.